45,000 Shares in Medtronic PLC $MDT Bought by Sivik Global Healthcare LLC

Sivik Global Healthcare LLC acquired a new stake in Medtronic PLC (NYSE:MDT) during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 45,000 shares of the medical technology company’s stock, valued at approximately $3,883,000. Medtronic accounts for 2.4% of Sivik Global Healthcare LLC’s holdings, making the stock its 19th largest holding.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Sax Wealth Advisors LLC grew its stake in Medtronic by 6.5% in the third quarter. Sax Wealth Advisors LLC now owns 6,106 shares of the medical technology company’s stock valued at $527,000 after purchasing an additional 370 shares in the last quarter. NorthCrest Asset Manangement LLC increased its position in shares of Medtronic by 14.2% during the 3rd quarter. NorthCrest Asset Manangement LLC now owns 105,147 shares of the medical technology company’s stock worth $9,227,000 after purchasing an additional 13,074 shares during the last quarter. HF Advisory Group LLC raised its stake in shares of Medtronic by 5.2% during the 3rd quarter. HF Advisory Group LLC now owns 23,577 shares of the medical technology company’s stock worth $2,034,000 after purchasing an additional 1,165 shares in the last quarter. Valley Wealth Managers Inc. raised its stake in shares of Medtronic by 3.1% during the 3rd quarter. Valley Wealth Managers Inc. now owns 54,193 shares of the medical technology company’s stock worth $4,676,000 after purchasing an additional 1,631 shares in the last quarter. Finally, Atlas Brown Inc. raised its stake in shares of Medtronic by 5.5% during the 3rd quarter. Atlas Brown Inc. now owns 2,758 shares of the medical technology company’s stock worth $238,000 after purchasing an additional 145 shares in the last quarter. 82.06% of the stock is owned by institutional investors.

Insider Activity at Medtronic

In related news, EVP Harry Kiil sold 1,483 shares of Medtronic stock in a transaction dated Wednesday, September 16th. The shares were sold at an average price of $93.65, for a total transaction of $138,882.95. Following the completion of the sale, the executive vice president owned 42,186 shares of the company’s stock, valued at approximately $3,950,718.90. The trade was a 3.40% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 0.27% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently commented on MDT shares. UBS Group increased their price objective on Medtronic from $100.00 to $110.00 and gave the company a “buy” rating in a report on Thursday, September 3rd. BTIG Research dropped their price target on shares of Medtronic from $100.00 to $99.00 and set a “buy” rating on the stock in a research report on Monday. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $118.00 price target on shares of Medtronic in a research report on Wednesday, September 2nd. Truist Financial reiterated a “hold” rating and issued a $99.00 price target (up from $86.00) on shares of Medtronic in a research note on Wednesday, September 2nd. Finally, Piper Sandler reissued a “neutral” rating on shares of Medtronic in a research report on Monday, August 10th. Eighteen research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $102.88.

Medtronic News Summary

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: MiniMed exchange offer was oversubscribed: Medtronic announced it will exchange all of its remaining 252.8 million MiniMed Group (NASDAQ: MMED) shares. The transaction advances the separation of the diabetes-device business and could allow investors to value Medtronic’s continuing operations more directly. The reported 18.3% proration indicates demand exceeded the shares available in the offer. Medtronic Announces Preliminary Results of MiniMed Exchange Offer
• Positive Sentiment: Growth opportunities remain attractive: The global bioelectronic-medicine device market is projected to expand at approximately a 17% annual rate through 2030. Medtronic’s position in neuromodulation and closed-loop technologies could provide exposure to this expanding market. Global Bioelectronic Medicine Device Market 2026
• Neutral Sentiment: Valuation and outlook support the shares: Commentary highlights Medtronic’s modest valuation relative to the broader market and an improving growth outlook. Its latest reported quarter also exceeded earnings and revenue expectations, with revenue up 13.7% year over year. Medtronic’s Modest Valuation Meets an Improving Growth Outlook
• Negative Sentiment: Short interest increased significantly: A larger bearish position in MDT suggests some investors are positioning for weakness and may weigh on sentiment, despite the company’s fundamental catalysts. Medtronic Sees Significant Increase in Short Interest
• Negative Sentiment: BTIG lowered its price target: The firm reduced its target from $100 to $99, although it retained a “buy” rating. The cut signals somewhat less near-term upside and tempers the otherwise constructive analyst view. Medtronic Price Target Cut by BTIG Research

Medtronic Stock Performance

Shares of NYSE MDT traded up $0.31 during midday trading on Tuesday, hitting $92.24. 6,194,355 shares of the company’s stock were exchanged, compared to its average volume of 10,820,273. The company’s 50 day moving average price is $90.38 and its 200 day moving average price is $84.80. Medtronic PLC has a 12 month low of $73.31 and a 12 month high of $106.33. The firm has a market capitalization of $117.99 billion, a PE ratio of 22.71, a price-to-earnings-growth ratio of 2.02 and a beta of 0.55. The company has a quick ratio of 1.54, a current ratio of 2.07 and a debt-to-equity ratio of 0.50.

Medtronic (NYSE:MDT) last released its quarterly earnings data on Tuesday, September 1st. The medical technology company reported $1.45 EPS for the quarter, topping analysts’ consensus estimates of $1.39 by $0.06. Medtronic had a net margin of 13.93% and a return on equity of 14.78%. The firm had revenue of $9.76 billion during the quarter, compared to analysts’ expectations of $9.55 billion. During the same period in the previous year, the business posted $1.26 earnings per share. The company’s revenue for the quarter was up 13.7% compared to the same quarter last year. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. As a group, analysts predict that Medtronic PLC will post 5.98 earnings per share for the current fiscal year.

Medtronic Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, October 16th. Stockholders of record on Friday, September 25th will be paid a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a dividend yield of 3.1%. The ex-dividend date is Friday, September 25th. Medtronic’s dividend payout ratio (DPR) is currently 70.94%.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures devices, therapies and healthcare solutions for treating chronic and acute conditions. Its products are used in areas including cardiac and vascular care, neuroscience, medical and surgical procedures, and diabetes management.

The company’s portfolio includes pacemakers, implantable cardioverter-defibrillators, cardiac ablation systems, stents and other cardiovascular products; neuromodulation systems, deep-brain stimulation devices and spinal technologies; surgical instruments, robotic-assisted surgery systems and gastrointestinal diagnostic tools; and insulin pumps and related diabetes technologies.

Medtronic traces its origins to 1949, when Earl Bakken and Palmer Hermundslie founded the company in Minneapolis, Minnesota.